Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887248 | 0.87 | GPR35 (0.40) | GPR35LOXL2ELANECCNE2CDK1 | |
| SCHEMBL30307581 | 0.87 | GPR35 (0.40) | GPR35LOXL2ELANECCNE2CDK1 | |
| SCHEMBL23887207 | 0.82 | PIK3CA (0.37) | ELANECCNE2CDK1CDK4CCNB1 | |
| SCHEMBL23887366 | 0.81 | LOXL2 (0.54) | GPR35LOXL2ELANECCNE2CDK1 | |
| SCHEMBL30434136 | 0.81 | SIRT2 (0.38) | GPR35CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL23887120 | 0.81 | CCNE2 (0.33) | GPR35CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL23887048 | 0.78 | PIK3CA (0.34) | CCNE2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL23887283 | 0.76 | CDK1 (0.38) | GPR35LOXL2ELANECCNE2CDK1 | |
| SCHEMBL30564411 | 0.76 | CCNE2 (0.31) | CCNE2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL30768042 | 0.75 | KDM4E (0.34) | GPR35CCNE2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115956075-A | Allosteric enone inhibitors of phosphoinositide 3-kinases (PI 3 ks) for the treatment of diseases associated with PI3K modulation | 佩特拉制药公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4126851-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | Petra Pharma Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2021202964-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | PETRA PHARMA CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | GPR35 1284/4885LOXL2 4671/4885ELANE 4514/4885 |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | GPR35 1284/4885LOXL2 4671/4885ELANE 4514/4885 |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, AKT3, PIK3R1 | GPR35 1284/4885LOXL2 4671/4885ELANE 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.